

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

HEALTH TECHNOLOGY APPRAISAL PROGRAMME

Equality impact assessment – Guidance development

STA Teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes

The impact on equality has been assessed during this appraisal according to the principles of the NICE equality scheme.

Final draft guidance

(when draft guidance issued)

1. Have any additional potential equality issues been raised during the consultation, and, if so, how has the committee addressed these?

The following additional issues were raised at consultation and at the second and third committee meeting:

- Increased rates of diabetic ketoacidosis (DKA) may be associated with people living in more deprived areas, so there may be additional benefit in terms of reducing DKA in this population.
- Diabetes distress in caregivers of young people with T1D is associated with deprivation and protected characteristics.

The committee also considered the impact on health inequalities for people who are underserved do not have sufficient access to or are not represented in research studies. At the second committee meeting, it requested extra evidence on the generalisability of ELSA to underserved populations, which was provided before the third committee meeting.

Socioeconomic status is not a protected characteristic under the Equality Act 2010. Issues related to differences in prevalence or incidence of a condition, or access to care, are not issues that can be addressed by a NICE technology appraisal recommendation. It took into account the potential

particular benefits of teplizumab in some population groups in its decision making

2. If the recommendations have changed after consultation, are there any recommendations that make it more difficult in practice for a specific group to access the technology compared with other groups? If so, what are the barriers to, or difficulties with, access for the specific group?

No

3. If the recommendations have changed after consultation, is there potential for the recommendations to have an adverse impact on people with disabilities because of something that is a consequence of the disability?

No

4. If the recommendations have changed after consultation, are there any recommendations or explanations that the committee could make to remove or alleviate barriers to, or difficulties with, access identified in questions 2 and 3, or otherwise fulfil NICE's obligations to promote equality?

No

5. Have the committee's considerations of equality issues been described in the final draft guidance, and, if so, where?

Yes, in section 3.21 of the FDG.

Approved by Associate Director (name): Ian Watson

Date: 15 June 2026

Technology appraisals: Guidance development

Equality impact assessment for the single technology appraisal of teplizumab for delaying the onset of stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes 2 of 2

Issue date: June 2026